<?xml version="1.0" encoding="UTF-8"?>
			<!DOCTYPE ijbi.edwiserinternational.com [
<!ELEMENT channel (title,link,description,language,managingEditor,webMaster,copyright,image,item,item,item,item,item,item,item,item)>
<!ELEMENT title (#PCDATA)>
<!ELEMENT link (#PCDATA)>
<!ELEMENT language (#PCDATA)>
<!ELEMENT managingEditor (#PCDATA)>
<!ELEMENT webMaster (#PCDATA)>
<!ELEMENT copyright (#PCDATA)>

<!ELEMENT image (title,link,url,width,height)>
<!ELEMENT url (#PCDATA)>
<!ELEMENT width (#PCDATA)>
<!ELEMENT height (#PCDATA)>

<!ELEMENT item (title,pubDate,link,author,comments,category,description)>
<!ELEMENT pubDate (#PCDATA)>
<!ELEMENT author (#PCDATA)>
<!ELEMENT comments (#PCDATA)>
<!ELEMENT category (#PCDATA)>
<!ELEMENT description (#PCDATA)>

]>
		<channel>
<title>International-Journal-of-Biomedical-Investigation-ISSUE VOLUME Volume 1 ISSUE Issue 1</title>
<link>http://ijbi.edwiserinternational.com/rss-feed.php</link>
<description>
International-Journal-of-Biomedical-Investigation: VOLUME Volume 1 ISSUE Issue 1, Jan-Mar 2018
</description>
<language>en-us</language>
<managingEditor>editor@edwiserinternational.com</managingEditor>
<webMaster>editor@edwiserinternational.com</webMaster>
<copyright>editor@edwiserinternational.com</copyright>
<image>
<title>International-Journal-of-Biomedical-Investigation-ISSUE VOLUME Volume 1 ISSUE Issue 1</title>
<link>http://ijbi.edwiserinternational.com/rss-feed.php</link>
<url>http://ijbi.edwiserinternational.com/img/logo1.png</url>
<width>360</width>
<height>109</height>
</image><item>
		<title>Periodontal-Disease</title>
		<pubDate>22-Dec-2018</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/xR00s6.pdf</link>
		<author>Jose-Ricardo-Kina</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Periodontal Disease]]>}</description>
		</item><item>
		<title>Pharmacognostic-and-Preliminary-Phytochemical-Evaluation-of-the-leaves-of-Leucas-zeylanica</title>
		<pubDate>22-Dec-2018</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/2WVTaE.pdf</link>
		<author>Radhika-B-Srilekha-T-Chaitanya-S-Sandhya-K-Sai</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Leucas zeylanica Linn belongs to the family Lamiaceae, the leaves of Leucas zeylanica are dried andpowdered. Extraction was done by using two solvents like acetone andethanol by soxhalation method. In this present study, the pharmacognostic andpreliminary phytochemical screening was performed for two extracts it indicates the presences of carbohydrates, flavonoids, alkaloids, glycosides.]]>}</description>
		</item><item>
		<title>Thyroid-Hormone-Enhances-Neurite-Outgrowth-in-Neuroscreen-1-Cells</title>
		<pubDate>28-Dec-2018</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/7NOW82.pdf</link>
		<author>Oldham-CE-Wooten-CJ-Williams-AB-Dixon-S-Lopez-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Objectives: Alzheimers disease (AD) is a neurodegenerative disorder that affects millions of individuals. Moreover, hypothyroidism has been identified as one of the risk factors that may contribute to the development of AD. Here, we investigated whether there was a correlation among expression levels of proteins involved in the formation of AD lesions, neurite outgrowth, and thyroid hormone levels.Methods: Cells were grown in media supplemented with different levels of 3,5,3-triiodothyronine (T3) and then processed for neurite outgrowth and to prepare RNA samples. RNA samples were analysed using quantitative real-time PCR. Protein levels were measured using in cell-Western blotting analysis.Results: By using neurite outgrowth studies, it was demonstrated that T3 treatment enhanced neurite outgrowth in NS-1 cells in a time- and dose-dependent manner. Quantitative real-time PCR studies further confirmed that NS-1 cells expressed substantial levels of TR and significantly less TR, either of which could be responsible for the T3-dependent effects on neurite outgrowth. Although the overall tau protein expression was not affected in response to T3 treatment, the splicing of tau exon 10 was impacted in the direction of producing more tau molecules that excluded the exon (tau 3R).Conclusion: The results of this study are critical not only to understand the probable link between hypothyroidism and AD but also in providing the basis for future prevention and treatment of AD in hypothyroid patients.]]>}</description>
		</item><item>
		<title>Phytochemical-Evaluation-of-Senna-tora-Linn</title>
		<pubDate>22-Dec-2018</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/GVfNrJ.pdf</link>
		<author>Gaykhe-RC-Kadam-VB</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[The seasonal variation of protein, amino acid, alkaloid and lipid content have been investigated from leaves, stem, root and seeds of Senna tora. Comparative account of protein contents of Senna tora showed higher level in seeds (26.648 mg/g dry wt.) than leaves (range 5.763 to 6.544 mg/g dry wt.), stem (range 3.785 to 4.341 mg/g dry wt.) and root (range 1.871 to 2.349 mg/g dry wt.). Comparative account of amino acid contents of Senna tora showed higher level in seeds (10.436 mg/g dry wt.) than leaves (range 0.085 to 1.143 mg/g dry wt.), stem (range 0.872 to 0.943 mg/g dry wt.) and root (range 0.287 to 0.324 mg/g dry wt.). Comparative account of alkaloid contents of Senna tora showed higher level in seeds (5.938 mg/g dry wt.) than leaves (range 3.109 to 3.749 mg/g dry wt.), stem (range 2.083 to 2.378 mg/g dry wt.) and root (range 0.854 to 1.015 mg/g dry wt.). Comparative account of lipid contents of Senna tora showed higher level in seeds (14.730 mg/g dry wt.) than leaves (range 8.638 to 9.630 mg/g dry wt.), stem (range 3.682 to 4.319 mg/g dry wt.) and root (range 1.232 to 1.914 mg/g dry wt.).]]>}</description>
		</item><item>
		<title>RP-HPLC-Method-Development-and-Validation-for-Quantitative-Estimation-of-Tiotropium-Bromide-and-Oldaterol</title>
		<pubDate>22-Dec-2018</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/GQERjk.pdf</link>
		<author>Suthakaran-R-Bikshapathi-DVRN-Sudha-Parimala</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[A simple and selective LC method is described for the determination of Tiotropium Bromide and Olodaterol dosage forms. Chromatographic separation was achieved on a c18 column using mobile phase consisting of a mixture of 50 volumes of acetonitrile and 50 volumes of Triethyl-amine buffer with detection of 225 nm. Linearity was observed in the range 30-70 g/ml for Tiotropium Bromide (r2 =0.9987) and 40-80 g/ml for Olodaterol (r2 =0.9977) for the amount of drugs estimated by the proposed methods was in good agreement with the label claim. The proposed methods were validated. The accuracy of the methods was assessed by recovery studies at three different levels. Recovery experiments indicated the absence of interference from commonly encountered pharmaceutical additives. The method was found to be precise as indicated by the repeatability analysis, showing % RSD less than 2. All statistical data proves validity of the methods and can be used for routine analysis of pharmaceutical dosage form.]]>}</description>
		</item><item>
		<title>Inflammation-and-Breast-Cancer-A-Mini-Review</title>
		<pubDate>22-Dec-2018</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/k0ROnT.pdf</link>
		<author>Li-Pin-Kao</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Chronic inflammation is a critical factor in tumor progression. Adipocyte accumulation and cytokines storm during inflammation have a significant impact on breast cancer. The development of cancer arises from sites of infection, chronic irritation and inflammation. Furthermore, tumor seed in tumor microenvironment as seed and soil, orchestrated by inflammatory cells, is an indispensable for cells transformed into benign or malignancy status and further fostering proliferation, survival, and migration. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.]]>}</description>
		</item><item>
		<title>A-New-analytical-method-development-and-validation-of-Ambroxol-Montelukast-and-Levocetirizine-in-Tablet-dosage-form-by-RP-HPLC-method</title>
		<pubDate>22-Dec-2018</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/xtn5s8.pdf</link>
		<author>Suthakaran-R-Shankar-CH-Sudha-Parimala</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[A simple and selective LC method is described for the determination of Ambroxol, Montelukast and Levocetirizine in tablet dosage forms. Chromatographic separation was achieved on a c18 column using mobile phase consisting of a mixture of Triethylamine Buffer:ACN:Methanol (20:30:50) with detection of 280 nm. Linearity was observed in the range 7.7-22.5 g/ml for Ambroxol (r2=0.999) and 1.25-3.75 g/ml for Montelukast (r2=0.998) and 5-15 g/ml for Levocetirizine (r2=0.997) for the amount of drugs estimated by the proposed methods was in good agreement with the label claim. The proposed methods were validated. The accuracy of the methods was assessed by recovery studies at three different levels. Recovery experiments indicated the absence of interference from commonly encountered pharmaceutical additives. The method was found to be precise as indicated by the repeatability analysis, showing %RSD less than 2. All statistical data proves validity of the methods and can be used for routine analysis of pharmaceutical dosage form.]]>}</description>
		</item><item>
		<title>Potential-Link-Between-Proprotein-Convertase-SubtilisinKexin-Type-9-and-Alzheimers-Disease</title>
		<pubDate>28-Dec-2018</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/0FbXgV.pdf</link>
		<author>Oldham-CE-Powell-RS-Williams-ABet-al</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Alzheimers disease [AD] is not only the most common neurodegenerative disease but is also currently incurable. Proprotein convertase subtilisin/kexin-9 [PCSK9] is an indirect regulator of plasma low density lipoprotein [LDL] levels controlling LDL receptor expression at the plasma membrane. PCSK9 also appears to regulate the development of glucose intolerance, insulin resistance, abdominal obesity, inflammation, and hypertension, conditions that have been identified as risk factors for AD. PCSK9 levels also depend on age, sex, and ethnic background, factors associated with AD. Herein, we will review indirect evidence that suggests a link between PCSK9 levels and AD.]]>}</description>
		</item></channel>